Clinical Trial: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Change from baseline (Visit 3) of inferior region CFS score at 12 weeks. Inferior region CFS score range 0-4, where '0' represents no fluorescein staining and '4' represents severe staining on the cornea.
Original Primary Outcome: Change of inferior corneal fluorescein staining score. [ Time Frame: Baseline to Week 12 ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Rigel Pharmaceuticals
Dates:
Date Received: July 11, 2013
Date Started: July 2013
Date Completion:
Last Updated: August 9, 2016
Last Verified: August 2016
